Adekalant (H 345/52) is a new antiarrhythmic compound with low proarrhythmic activity. H 345/52 concentration-dependently blocked HERG-carried currents with an IC50 of 230 nM. H 345/52 preferentially bound to the open channel with unusually rapid kinetics and was trapped by channel closure. Voltage-independent behavior of H 345/52 was observed during both square-pulse and action potential clamp protocols. It is proposed that block of IKr is the principal mechanism by which H 345/52 delays repolarization in human myocardium. H 345/52 blocks I(Kr) with high potency and I(Ca) with somewhat lower potency and was found to delay ventricular repolarisation without substantially increasing temporal or spatial dispersion and without inducing early after-depolarisations or TdP.

Acebrochol is a neuroactive steroid that may act as a sedative and hypnotic, through the mechanism of altering ligand-gated ion channels and cell surface receptors.

Difemetorex is a stimulant drug of the piperidine class. It was used as an appetite suppressant, anorectic agent. Difemetorex has intolerable side effects such as insomnia, which limited its clinical use.

Dietifen is an anesthetic, vasodilator and antifungal agent. The main pharmacological feature of the drug is its ability to cause expansion of the coronary vessels. It also has a moderate spasmolytic activity (reduces spasms of the muscles of the intestine and other internal organs) and somewhat inhibits the conduction of nervous excitement through the vegetative nodes. Significant changes in blood pressure and pulse rate does not cause, does not possess hormonal (estrogenic) activity. It is indicated for the treatment of chronic coronary insufficiency, angina pectoris, severe forms of coronary sclerosis and pre-infarction conditions (simultaneously with anticoagulants).

Iosumetic Acid is a triiodoaminoisophthalic acid derivative patented by Schering A.-G. as contrast medium for direct and indirect lymphography.

Iotrizoic Acid is acylated amino acid derivative patented by Swiss pharmaceutical company Cilag-Chemie A.-G. as x-ray contrasting agent

Evatanepag (CP-533,536) is a prostaglandin E2 EP2 receptor agonist. It stimulates new bone formation on trabecular, endocortical, and periosteal surfaces and enhances fracture healing. Evatanepag was under development with Pfizer as a bone formation stimulant for therapeutic use in the healing of fractures.

Inproquone is a benzoquinone derivative used as a cytostatic and alkylating agent for cancer treatment

Iobutoic Acid is a Triiodo-hydroxybenzamide derivative patented by Laboratoires Andre Guerbet as x-ray contrast media in cholecystography and as a choleretic agent.